Chugai Pharmaceutical Co. Ltd.

Company Overview

Founded in 1925 and headquartered in Japan, Chugai Pharmaceuticals is a subsidiary of Roche Holding Ltd. (which owns ~62% of the company) that manufactures, sells, and markets pharmaceutical products in Japan and internationally.

The company offers a strong portfolio for oncology, joint disease and renal diseases. Oncology products include Kytril, Femara, Tarceva, Xeloda, Neutrogin, Rituxan, Herceptin and Avastin. Bone and joint disease products include Edirol, Altfarol, Suvenyl, Evista and Actemra. Renal disease products include Renagel, Oxaro, Epogin and Mircera. Chugai Pharmaceuticals also provides products for chronic hepatitis C, such as Copegus, CellCept, Pegasy, Sigmart and Tamiflu. It has various product candidates in oncology, bone and joint diseases, autoimmune diseases, and central nervous system diseases.

Chugai Pharmaceutical has a strategic alliance with Roche and a co-development and comarketing agreement with Taisho Pharmaceutical Co. Ltd. Roche’s subsidiary, Chugai Pharmaceuticals, manufactures, markets, and distributes Edirol, a drug used to treat various cancers, including breast cancer. In December 2021, Towa Pharmaceuticals approved a generic version of Chugai’s postmenopausal osteoporosis agent, Edirol.

Financial Highlights (FY 2024)

Company's Business Segments

• Pharmaceutical Products : The company provides pharmaceutical products and medical devices for patients, including ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta, and others.